Patients Have Rights To Their Own Device-Generated Data, FDA Clarifies

Patients have absolute rights to their own medical data as recorded by devices such as blood pressure and heart rhythm monitors, FDA clarified in an Oct. 27 guidance. It follows-up on a June 2016 draft guidance, as well as comments by patients and patient advocates at the first Patient Engagement Advisory Committee (PEAC) meeting held earlier this month.

Cellnovo pump on arm

Manufacturers and physicians need to share the patient-specific information that is recorded with vital signs devices like blood pressure monitors, implantable devices or diagnostics upon the patient's request, FDA clarified in a final guidance on the topic released Oct. 27.

"Providing patients with accurate and complete information about their diagnosis and treatment, including the data collected from medical devices like blood pressure or heart rhythm monitors, allows patients to be better informed about their health and more active

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America

Health Secretary Defends Spending Cuts During Senate Hearing On HHS Budget

 
• By 

Health and Human Services Secretary Robert F. Kennedy Jr. emphasized administrative cost reductions and defended budget decisions during a Senate hearing on HHS funding. Some senators, however, expressed concerns over the impacts spending cuts had on essential health programs.

Tariffs Threaten Medtech Innovation And US Position As World Leader, Whitaker Tells Lawmakers

 

During his testimony before US senators on the impact of tariffs on critical supply chains, AdvaMed’s Scott Whitaker said the Trump tariffs could jeopardize America’s preeminence in medtech. Other industry experts echoed similar concerns.

Califf Warns Progress May Be In Danger Due To ‘Decimated’ FDA Staff

 

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.